The team at MIT created the most comprehensive database of metabolites, their interactions with proteins, protein-protein interactions, drug-protein interactions, and …

“One-target-one-disease” paradigm has been around for decades, prompting numerous drug discovery programs focusing on identifying small molecules for targeting only …

In this interview, Dr. Jackie Hunter, CEO at BenevolentAI, provides insights into how the company’s AI-driven platform helps scientists create …

This is an interview with Niels Iversen Møller, a CEO, and Co-founder of Evaxion Biotech -- an immuno-informatics biotech from …

IBM developed machine learning models to analyze correlations between diseases and side effects commonly caused by the medications used to …

Virtual reality (VR) has been a hot topic in game industry lately, but now it finds its way to biopharmaceutical …